Epigenetics, autoimmunity and hematologic malignancies: A comprehensive review

Journal of Autoimmunity

Volumn 39, Issue 4, 2012, Pages 451-465

  Ngalamika, Owen ^a,c   Zhang, Yiqun ^a   Yin, Heng ^a   Zhao, Ming ^a   Gershwin, M Eric ^b   Lu, Qianjin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY TEACHING HOSPITAL   (Zambia)

Author keywords

Autoimmune disease; Epigenetics; Hematological malignancy; Th17 cells; Treg cells

Indexed keywords

CYTOKINE; DNA METHYLTRANSFERASE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE METHYLTRANSFERASE; INTERLEUKIN 17; INTERLEUKIN 17F; STAT3 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

AUTOIMMUNE DISEASE; AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME; AUTOIMMUNE POLYENDOCRINOPATHY CANDIDIASIS ECTODERMAL DYSTROPHY; AUTOIMMUNITY; B LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; COMMON VARIABLE IMMUNODEFICIENCY; CYTOKINE PRODUCTION; DNA MODIFICATION; DNA SEQUENCE; EPIGENETICS; FOXP3 GENE; GENE CONTROL; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HISTONE MODIFICATION; HUMAN; IMMUNE DEFICIENCY; IPEX SYNDROME; LYMPHOMA; MONOZYGOTIC TWINS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; TRANSCRIPTION REGULATION; TSDR GENE; WISKOTT ALDRICH SYNDROME;

ADULT; AUTOIMMUNITY; CELL DIFFERENTIATION; CHILD; EPIGENESIS, GENETIC; EPIGENOMICS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TWINS, MONOZYGOTIC;

EID: 84869881809     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.09.002     Document Type: Review

References (251)

1. Lister R., Pelizzola M., Dowen R.H., Hawkins R.D., Hon G., Tonti-Filippini J., et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462:315-322.
2. Hewagama A., Richardson B. The genetics and epigenetics of autoimmune diseases. Journal of Autoimmunity 2009, 33:3-11.
3. Zhao M., Sun Y., Gao F., Wu X., Tang J., Yin H., et al. Epigenetics and SLE: RFX1 downregulation causes CD11a and CD70 overexpression by altering epigenetic modifications in lupus CD4+ T cells. Journal of Autoimmunity 2010, 35:58-69.
4. Rong G., Zhou Y., Xiong Y., Zhou L., Geng H., Jiang T., et al. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clinical and Experimental Immunology 2009, 156:217-225.
5. Fischer A. Human immunodeficiency: connecting STAT3, Th17 and human mucosal immunity. Immunology and Cell Biology 2008, 86:549-551.
6. Stepkowski S.M., Chen W., Ross J.A., Nagy Z.S., Kirken R.A. STAT3: an important regulator of multiple cytokine functions. Transplantation 2008, 85:1372-1377.
7. Li C.R., Deiro M.F., Godebu E., Bradley L.M. IL-7 uniquely maintains FoxP3(+) adaptive Treg cells that reverse diabetes in NOD mice via integrin-beta7-dependent localization. Journal of Autoimmunity 2011, 37:217-227.
8. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
9. Chen Z., Lin F., Gao Y., Li Z., Zhang J., Xing Y., et al. FOXP3 and RORgammat: transcriptional regulation of Treg and Th17. International Immunopharmacology 2011, 11:536-542.
10. Huehn J., Polansky J.K., Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?. Nature Reviews Immunology 2009, 9:83-89.
11. Mantel P.Y., Ouaked N., Ruckert B., Karagiannidis C., Welz R., Blaser K., et al. Molecular mechanisms underlying FOXP3 induction in human T cells. Journal of Immunology 2006, 176:3593-3602.
12. Janson P.C., Winerdal M.E., Marits P., Thorn M., Ohlsson R., Winqvist O. FOXP3 promoter demethylation reveals the committed Treg population in humans. PloS One 2008, 3:e1612.
13. Kim H.P., Leonard W.J. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. The Journal of Experimental Medicine 2007, 204:1543-1551.
14. Venuprasad K., Huang H., Harada Y., Elly C., Subramaniam M., Spelsberg T., et al. The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nature Immunology 2008, 9:245-253.
15. Zorn E., Nelson E.A., Mohseni M., Porcheray F., Kim H., Litsa D., et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006, 108:1571-1579.
16. Burchill M.A., Yang J., Vogtenhuber C., Blazar B.R., Farrar M.A. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. Journal of Immunology 2007, 178:280-290.
17. Tone Y., Furuuchi K., Kojima Y., Tykocinski M.L., Greene M.I., Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nature Immunology 2008, 9:194-202.
18. Floess S., Freyer J., Siewert C., Baron U., Olek S., Polansky J., et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biology 2007, 5:e38.
19. Baron U., Floess S., Wieczorek G., Baumann K., Grutzkau A., Dong J., et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. European Journal of Immunology 2007, 37:2378-2389.
20. Nagar M., Vernitsky H., Cohen Y., Dominissini D., Berkun Y., Rechavi G., et al. Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD25-CD4+ T cells. International Immunology 2008, 20:1041-1055.
21. Polansky J.K., Kretschmer K., Freyer J., Floess S., Garbe A., Baron U., et al. DNA methylation controls Foxp3 gene expression. European Journal of Immunology 2008, 38:1654-1663.
22. Wieczorek G., Asemissen A., Model F., Turbachova I., Floess S., Liebenberg V., et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Research 2009, 69:599-608.
23. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nature Medicine 2007, 13:1299-1307.
24. Reilly C.M., Thomas M., Gogal R., Olgun S., Santo A., Sodhi R., et al. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. Journal of Autoimmunity 2008, 31:123-130.
25. Weaver C.T., Hatton R.D., Mangan P.R., Harrington L.E. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annual Review of Immunology 2007, 25:821-852.
26. McGeachy M.J., Cua D.J. Th17 cell differentiation: the long and winding road. Immunity 2008, 28:445-453.
27. Chen Z., Laurence A., O'Shea J.J. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Seminars in Immunology 2007, 19:400-408.
28. Chen Z., Tato C.M., Muul L., Laurence A., O'Shea J.J. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis and Rheumatism 2007, 56:2936-2946.
29. Liu X.K., Lin X., Gaffen S.L. Crucial role for nuclear factor of activated T cells in T cell receptor-mediated regulation of human interleukin-17. The Journal of Biological Chemistry 2004, 279:52762-52771.
30. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
31. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
32. Zhou L., Ivanov, Spolski R., Min R., Shenderov K., Egawa T., et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nature Immunology 2007, 8:967-974.
33. Aggarwal S., Ghilardi N., Xie M.H., de Sauvage F.J., Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. The Journal of Biological Chemistry 2003, 278:1910-1914.
34. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology 2005, 6:1123-1132.
35. Laurence A., Tato C.M., Davidson T.S., Kanno Y., Chen Z., Yao Z., et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007, 26:371-381.
36. Mathur A.N., Chang H.C., Zisoulis D.G., Stritesky G.L., Yu Q., O'Malley J.T., et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. Journal of Immunology 2007, 178:4901-4907.
37. Chen Z., Laurence A., Kanno Y., Pacher-Zavisin M., Zhu B.M., Tato C., et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:8137-8142.
38. Eberl G., Littman D.R. The role of the nuclear hormone receptor RORgammat in the development of lymph nodes and Peyer's patches. Immunological Reviews 2003, 195:81-90.
39. Sun Z., Unutmaz D., Zou Y.R., Sunshine M.J., Pierani A., Brenner-Morton S., et al. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science 2000, 288:2369-2373.
40. Kurebayashi S., Ueda E., Sakaue M., Patel D.D., Medvedev A., Zhang F., et al. Retinoid-related orphan receptor gamma (RORgamma) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:10132-10137.
41. Eberl G., Marmon S., Sunshine M.J., Rennert P.D., Choi Y., Littman D.R. An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. Nature Immunology 2004, 5:64-73.
42. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008, 28:29-39.
43. Li M.O., Wan Y.Y., Flavell R.A. T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity 2007, 26:579-591.
44. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annual Review of Immunology 2006, 24:99-146.
45. Martinez G.J., Zhang Z., Reynolds J.M., Tanaka S., Chung Y., Liu T., et al. Smad2 positively regulates the generation of Th17 cells. The Journal of Biological Chemistry 2010, 285:29039-29043.
46. Wilson N.J., Boniface K., Chan J.R., McKenzie B.S., Blumenschein W.M., Mattson J.D., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nature Immunology 2007, 8:950-957.
47. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nature Immunology 2007, 8:942-949.
48. Veldhoen M., Hocking R.J., Atkins C.J., Locksley R.M., Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006, 24:179-189.
49. Hu C.M., Jang S.Y., Fanzo J.C., Pernis A.B. Modulation of T cell cytokine production by interferon regulatory factor-4. The Journal of Biological Chemistry 2002, 277:49238-49246.
50. Brustle A., Heink S., Huber M., Rosenplanter C., Stadelmann C., Yu P., et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nature Immunology 2007, 8:958-966.
51. Moseley T.A., Haudenschild D.R., Rose L., Reddi A.H. Interleukin-17 family and IL-17 receptors. Cytokine and Growth Factor Reviews 2003, 14:155-174.
52. Ye P., Rodriguez F.H., Kanaly S., Stocking K.L., Schurr J., Schwarzenberger P., et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. The Journal of Experimental Medicine 2001, 194:519-527.
53. Hymowitz S.G., Filvaroff E.H., Yin J.P., Lee J., Cai L., Risser P., et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. The EMBO Journal 2001, 20:5332-5341.
54. Wright J.F., Guo Y., Quazi A., Luxenberg D.P., Bennett F., Ross J.F., et al. Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells. The Journal of Biological Chemistry 2007, 282:13447-13455.
55. Liang S.C., Long A.J., Bennett F., Whitters M.J., Karim R., Collins M., et al. An IL-17F/A heterodimer protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. Journal of Immunology 2007, 179:7791-7799.
56. Lan R.Y., Salunga T.L., Tsuneyama K., Lian Z.X., Yang G.X., Hsu W., et al. Hepatic IL-17 responses in human and murine primary biliary cirrhosis. Journal of Autoimmunity 2009, 32:43-51.
57. Starnes T., Robertson M.J., Sledge G., Kelich S., Nakshatri H., Broxmeyer H.E., et al. Cutting edge: IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates angiogenesis and endothelial cell cytokine production. Journal of Immunology 2001, 167:4137-4140.
58. Akimzhanov A.M., Yang X.O., Dong C. Chromatin remodeling of interleukin-17 (IL-17)-IL-17F cytokine gene locus during inflammatory helper T cell differentiation. The Journal of Biological Chemistry 2007, 282:5969-5972.
59. Roh T.Y., Cuddapah S., Cui K., Zhao K. The genomic landscape of histone modifications in human T cells. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:15782-15787.
60. Mukasa R., Balasubramani A., Lee Y.K., Whitley S.K., Weaver B.T., Shibata Y., et al. Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. Immunity 2010, 32:616-627.
61. Yang X.P., Ghoreschi K., Steward-Tharp S.M., Rodriguez-Canales J., Zhu J., Grainger J.R., et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nature Immunology 2011, 12:247-254.
62. Nakajima H., Brindle P.K., Handa M., Ihle J.N. Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription. The EMBO Journal 2001, 20:6836-6844.
63. Li J., Wang J., Nawaz Z., Liu J.M., Qin J., Wong J. Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. The EMBO Journal 2000, 19:4342-4350.
64. Nagy L., Kao H.Y., Chakravarti D., Lin R.J., Hassig C.A., Ayer D.E., et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 1997, 89:373-380.
65. Rauen T., Hedrich C.M., Juang Y.T., Tenbrock K., Tsokos G.C. cAMP-responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus. The Journal of Biological Chemistry 2011, 286:43437-43446.
66. Juang Y.T., Rauen T., Wang Y., Ichinose K., Benedyk K., Tenbrock K., et al. Transcriptional activation of the cAMP-responsive modulator promoter in human T cells is regulated by protein phosphatase 2A-mediated dephosphorylation of SP-1 and reflects disease activity in patients with systemic lupus erythematosus. The Journal of Biological Chemistry 2011, 286:1795-1801.
67. Kyttaris V.C., Wang Y., Juang Y.T., Weinstein A., Tsokos G.C. CAMP response element modulator a expression in patients with systemic lupus erythematosus. Lupus 2006, 15:840-844.
68. Tenbrock K., Juang Y.T., Leukert N., Roth J., Tsokos G.C. The transcriptional repressor cAMP response element modulator alpha interacts with histone deacetylase 1 to repress promoter activity. Journal of Immunology 2006, 177:6159-6164.
69. Rosen F.S., Cooper M.D., Wedgwood R.J. The primary immunodeficiencies. The New England Journal of Medicine 1995, 333:431-440.
70. Thabet Y., Canas F., Ghedira I., Youinou P., Mageed R.A., Renaudineau Y. Altered patterns of epigenetic changes in systemic lupus erythematosus and auto-antibody production: Is there a link?. Journal of Autoimmunity 2012, 39:154-160.
71. Bakalov V.K., Gutin L., Cheng C.M., Zhou J., Sheth P., Shah K., et al. Autoimmune disorders in women with turner syndrome and women with karyotypically normal primary ovarian insufficiency. Journal of Autoimmunity 2012, 38:315-321.
72. Zhang Q., Long H., Liao J., Zhao M., Liang G., Wu X., et al. Inhibited expression of hematopoietic progenitor kinase 1 associated with loss of jumonji domain containing 3 promoter binding contributes to autoimmunity in systemic lupus erythematosus. Journal of Autoimmunity 2011, 37:180-189.
73. Maciejewska-Rodrigues H., Karouzakis E., Strietholt S., Hemmatazad H., Neidhart M., Ospelt C., et al. Epigenetics and rheumatoid arthritis: the role of SENP1 in the regulation of MMP-1 expression. Journal of Autoimmunity 2010, 35:15-22.
74. Youinou P., Pers J.O., Gershwin M.E., Shoenfeld Y. Geo-epidemiology and autoimmunity. Journal of Autoimmunity 2010, 34:J163-J167.
75. Calvanese V., Lara E., Fraga M.F. Epigenetic code and self-identity. Advances in Experimental Medicine and Biology 2012, 738:236-255.
76. Brooks W.H., Le Dantec C., Pers J.O., Youinou P., Renaudineau Y. Epigenetics and autoimmunity. Journal of Autoimmunity 2010, 34:J207-J219.
77. Burute M., Gottimukkala K., Galande S. Chromatin organizer SATB1 is an important determinant of T-cell differentiation. Immunology and Cell Biology 2012.
78. Zhu Y., van Essen D., Saccani S. Cell-type-specific control of enhancer activity by H3K9 trimethylation. Molecular Cell 2012, 46:408-423.
79. Calvanese V., Fraga M.F. Epigenetics of embryonic stem cells. Advances in Experimental Medicine and Biology 2012, 741:231-253.
80. Iyer S.S., Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Critical Reviews in Immunology 2012, 32:23-63.
81. Salavoura K., Kolialexi A., Tsangaris G., Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Research 2008, 28:1263-1269.
82. Arkwright P.D., Abinun M., Cant A.J. Autoimmunity in human primary immunodeficiency diseases. Blood 2002, 99:2694-2702.
83. Bussone G., Mouthon L. Autoimmune manifestations in primary immune deficiencies. Autoimmunity Reviews 2009, 8:332-336.
84. Jesus A.A., Duarte A.J., Oliveira J.B. Autoimmunity in hyper-IgM syndrome. Journal of Clinical Immunology 2008, 28(Suppl. 1):S62-S66.
85. Filipovich A.H., Mathur A., Kamat D., Shapiro R.S. Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Research 1992, 52:5465s-5467s.
86. Dominguez O., Giner M.T., Alsina L., Martin M.A., Lozano J., Plaza A.M. [Clinical phenotypes associated with selective IgA deficiency: a review of 330 cases and a proposed follow-up protocol]. Annals of Pediatric (Barc) 2012, 76:261-267.
87. Shkalim V., Monselize Y., Segal N., Zan-Bar I., Hoffer V., Garty B.Z. Selective IgA deficiency in children in Israel. Journal of Clinical Immunology 2010, 30:761-765.
88. Liblau R.S., Bach J.F. Selective IgA deficiency and autoimmunity. International Archives of Allergy and Immunology 1992, 99:16-27.
89. Wang J., Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). Journal of Autoimmunity 2005, 25:57-62.
90. Boileau J., Mouillot G., Gerard L., Carmagnat M., Rabian C., Oksenhendler E., et al. Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study. Journal of Autoimmunity 2011, 36:25-32.
91. Mueller B.U., Pizzo P.A. Cancer in children with primary or secondary immunodeficiencies. The Journal of Pediatrics 1995, 126:1-10.
92. Cunningham-Rundles C., Cooper D.L., Duffy T.P., Strauchen J. Lymphomas of mucosal-associated lymphoid tissue in common variable immunodeficiency. American Journal of Hematology 2002, 69:171-178.
93. Straus S.E., Jaffe E.S., Puck J.M., Dale J.K., Elkon K.B., Rosen-Wolff A., et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001, 98:194-200.
94. Turbyville J.C., Rao V.K. The autoimmune lymphoproliferative syndrome: a rare disorder providing clues about normal tolerance. Autoimmunity Reviews 2010, 9:488-493.
95. Wildin R.S., Smyk-Pearson S., Filipovich A.H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. Journal of Medical Genetics 2002, 39:537-545.
96. Elhasid R., Bergman R., Etzioni A. Autoimmunity in severe combined immunodeficiency (SCID). Blood 2002, 100:2677-2678. [author reply 8-9].
97. Milner J.D., Fasth A., Etzioni A. Autoimmunity in severe combined immunodeficiency (SCID): lessons from patients and experimental models. Journal of Clinical Immunology 2008, 28(Suppl. 1):S29-S33.
98. Catucci M., Castiello M.C., Pala F., Bosticardo M., Villa A. Autoimmunity in Wiskott-Aldrich syndrome: an unsolved Enigma. Frontiers in Immunology 2012, 3:209.
99. Cleland S.Y., Siegel R.M. Wiskott-Aldrich Syndrome at the nexus of autoimmune and primary immunodeficiency diseases. FEBS Letters 2011, 585:3710-3714.
100. Ochs H.D., Thrasher A.J. The Wiskott-Aldrich syndrome. The Journal of Allergy and Clinical Immunology 2006, 117:725-738. [quiz 39].
101. Fisher S.G., Fisher R.I. The epidemiology of non-Hodgkin's lymphoma. Oncogene 2004, 23:6524-6534.
102. Winkelstein J.A., Marino M.C., Johnston R.B., Boyle J., Curnutte J., Gallin J.I., et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine 2000, 79:155-169.
103. Kersey J.H., Shapiro R.S., Filipovich A.H. Relationship of immunodeficiency to lymphoid malignancy. The Pediatric Infectious Disease Journal 1988, 7:S10-S12.
104. Shapiro R.S. Malignancies in the setting of primary immunodeficiency: Implications for hematologists/oncologists. American Journal of Hematology 2011, 86:48-55.
105. Leechawengwongs E., Shearer W.T. Lymphoma complicating primary immunodeficiency syndromes. Current Opinion in Hematology 2012, 19:305-312.
106. Cotelingam J.D., Witebsky F.G., Hsu S.M., Blaese R.M., Jaffe E.S. Malignant lymphoma in patients with the Wiskott-Aldrich syndrome. Cancer Investigation 1985, 3:515-522.
107. Wheat W.H., Cool C.D., Morimoto Y., Rai P.R., Kirkpatrick C.H., Lindenbaum B.A., et al. Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency. The Journal of Experimental Medicine 2005, 202:479-484.
108. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nature Genetics 2001, 27:20-21.
109. Fontenot J.D., Rasmussen J.P., Williams L.M., Dooley J.L., Farr A.G., Rudensky A.Y. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005, 22:329-341.
110. Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299:1057-1061.
111. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nature Immunology 2003, 4:330-336.
112. Gambineri E., Perroni L., Passerini L., Bianchi L., Doglioni C., Meschi F., et al. Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. The Journal of Allergy and Clinical Immunology 2008, 122:1105-1112. e1.
113. Ochs H.D., Gambineri E., Torgerson T.R. IPEX, FOXP3 and regulatory T-cells: a model for autoimmunity. Immunologic Research 2007, 38:112-121.
114. Powell B.R., Buist N.R., Stenzel P. An X-linked syndrome of diarrhea, polyendocrinopathy, and fatal infection in infancy. The Journal of Pediatrics 1982, 100:731-737.
115. Barzaghi F., Passerini L., Gambineri E., Ciullini Mannurita S., Cornu T., Kang E.S., et al. Demethylation analysis of the FOXP3 locus shows quantitative defects of regulatory T cells in IPEX-like syndrome. Journal of Autoimmunity 2012, 38:49-58.
116. Rieux-Laucat F., Le Deist F., Fischer A. Autoimmune lymphoproliferative syndromes: genetic defects of apoptosis pathways. Cell Death and Differentiation 2003, 10:124-133.
117. Worth A., Thrasher A.J., Gaspar H.B. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype. British Journal of Haematology 2006, 133:124-140.
118. Fleisher T.A. The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis. Immunologic Research 2008, 40:87-92.
119. Rieux-Laucat F., Blachere S., Danielan S., De Villartay J.P., Oleastro M., Solary E., et al. Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant expression of the clinical manifestations. Blood 1999, 94:2575-2582.
120. Pensati L., Costanzo A., Ianni A., Accapezzato D., Iorio R., Natoli G., et al. Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology 1997, 113:1384-1389.
121. Wong C.S., Arkwright P.D., Rieux-Laucat F., Cant A.J., Stevens R.F., Judge M.R. Childhood linear IgA disease in association with autoimmune lymphoproliferative syndrome. The British Journal of Dermatology 2004, 150:578-580.
122. Fang B.S., Sneller M.C., Straus S.E., Frenkel L., Dale J.K., Rick M.E. Report of a factor VIII inhibitor in a patient with autoimmune lymphoproliferative syndrome. American Journal of Hematology 2000, 64:214-217.
123. Rao V.K., Straus S.E. Causes and consequences of the autoimmune lymphoproliferative syndrome. Hematology 2006, 11:15-23.
124. Gronbaek K., Straten P.T., Ralfkiaer E., Ahrenkiel V., Andersen M.K., Hansen N.E., et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998, 92:3018-3024.
125. Nagamine K., Peterson P., Scott H.S., Kudoh J., Minoshima S., Heino M., et al. Positional cloning of the APECED gene. Nature Genetics 1997, 17:393-398.
126. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nature Genetics 1997, 17:399-403.
127. Mathis D., Benoist C. A decade of AIRE. Nature Reviews Immunology 2007, 7:645-650.
128. Villasenor J., Benoist C., Mathis D. AIRE and APECED: molecular insights into an autoimmune disease. Immunological Reviews 2005, 204:156-164.
129. Ahonen P., Myllarniemi S., Sipila I., Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. The New England Journal of Medicine 1990, 322:1829-1836.
130. Betterle C., Greggio N.A., Volpato M. Clinical review 93: autoimmune polyglandular syndrome type 1. The Journal of Clinical Endocrinology and Metabolism 1998, 83:1049-1055.
131. Ramsey C., Winqvist O., Puhakka L., Halonen M., Moro A., Kampe O., et al. Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Human Molecular Genetics 2002, 11:397-409.
132. Notarangelo L.D., Miao C.H., Ochs H.D. Wiskott-Aldrich syndrome. Current Opinion in Hematology 2008, 15:30-36.
133. Dupuis-Girod S., Medioni J., Haddad E., Quartier P., Cavazzana-Calvo M., Le Deist F., et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 2003, 111:e622-e627.
134. Sullivan K.E., Mullen C.A., Blaese R.M., Winkelstein J.A. A multiinstitutional survey of the Wiskott-Aldrich syndrome. The Journal of Pediatrics 1994, 125:876-885.
135. Lopes-da-Silva S., Rizzo L.V. Autoimmunity in common variable immunodeficiency. Journal of Clinical Immunology 2008, 28(Suppl. 1):S46-S55.
136. Chua I., Quinti I., Grimbacher B. Lymphoma in common variable immunodeficiency: interplay between immune dysregulation, infection and genetics. Current Opinion in Hematology 2008, 15:368-374.
137. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
138. Bacchetta R., Passerini L., Gambineri E., Dai M., Allan S.E., Perroni L., et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. The Journal of Clinical Investigation 2006, 116:1713-1722.
139. Torgerson T.R., Ochs H.D. Immune dysregulation, polyendocrinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. The Journal of Allergy and Clinical Immunology 2007, 120:744-750. [quiz 51-2].
140. Kekalainen E., Tuovinen H., Joensuu J., Gylling M., Franssila R., Pontynen N., et al. A defect of regulatory T cells in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Journal of Immunology 2007, 178:1208-1215.
141. Adriani M., Aoki J., Horai R., Thornton A.M., Konno A., Kirby M., et al. Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. Clinical Immunology 2007, 124:41-48.
142. Humblet-Baron S., Sather B., Anover S., Becker-Herman S., Kasprowicz D.J., Khim S., et al. Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. The Journal of Clinical Investigation 2007, 117:407-418.
143. Maillard M.H., Cotta-de-Almeida V., Takeshima F., Nguyen D.D., Michetti P., Nagler C., et al. The Wiskott-Aldrich syndrome protein is required for the function of CD4(+)CD25(+)Foxp3(+) regulatory T cells. The Journal of Experimental Medicine 2007, 204:381-391.
144. Marangoni F., Trifari S., Scaramuzza S., Panaroni C., Martino S., Notarangelo L.D., et al. WASP regulates suppressor activity of human and murine CD4(+)CD25(+)FOXP3(+) natural regulatory T cells. The Journal of Experimental Medicine 2007, 204:369-380.
145. Torgerson T.R., Ochs H.D. Regulatory T cells in primary immunodeficiency diseases. Current Opinion in Allergy and Clinical Immunology 2007, 7:515-521.
146. Westerberg L.S., Klein C., Snapper S.B. Breakdown of T cell tolerance and autoimmunity in primary immunodeficiency-lessons learned from monogenic disorders in mice and men. Current Opinion in Immunology 2008, 20:646-654.
147. Waterfield M., Anderson M.S. Clues to immune tolerance: the monogenic autoimmune syndromes. Annals of the New York Academy of Sciences 2010, 1214:138-155.
148. Cheng M.H., Anderson M.S. Monogenic autoimmunity. Annual Review of Immunology 2012, 30:393-427.
149. Wang J., Ke X.Y. The four types of Tregs in malignant lymphomas. Journal of Hematology and Oncology 2011, 4:50.
150. Lin H., Sun X.F., Zhen Z.J., Xia Y., Ling J.Y., Huang H.Q., et al. [Correlation between peripheral blood CD4+CD25high CD127low regulatory T cell and clinical characteristics of patients with non-Hodgkin's lymphoma]. Ai zheng = Aizheng = Chinese Journal of Cancer 2009, 28:1186-1192.
151. Elpek K.G., Lacelle C., Singh N.P., Yolcu E.S., Shirwan H. CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. Journal of Immunology 2007, 178:6840-6848.
152. Ishida T., Ueda R. Immunopathogenesis of lymphoma: focus on CCR4. Cancer Science 2011, 102:44-50.
153. Li J., Qian C.N., Zeng Y.X. Regulatory T cells and EBV associated malignancies. International Immunopharmacology 2009, 9:590-592.
154. Minegishi Y., Saito M., Tsuchiya S., Tsuge I., Takada H., Hara T., et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448:1058-1062.
155. Holland S.M., DeLeo F.R., Elloumi H.Z., Hsu A.P., Uzel G., Brodsky N., et al. STAT3 mutations in the hyper-IgE syndrome. The New England Journal of Medicine 2007, 357:1608-1619.
156. Grimbacher B., Holland S.M., Gallin J.I., Greenberg F., Hill S.C., Malech H.L., et al. Hyper-IgE syndrome with recurrent infections-an autosomal dominant multisystem disorder. The New England Journal of Medicine 1999, 340:692-702.
157. Milner J.D., Brenchley J.M., Laurence A., Freeman A.F., Hill B.J., Elias K.M., et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452:773-776.
158. Puel A., Cypowyj S., Bustamante J., Wright J.F., Liu L., Lim H.K., et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011, 332:65-68.
159. Chandesris M.O., Melki I., Natividad A., Puel A., Fieschi C., Yun L., et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: molecular, cellular, and clinical features from a French national survey. Medicine 2012, 91:e1-e19.
160. Yamazaki-Nakashimada M., Zaltzman-Girshevich S., Garcia de la Puente S., De Leon-Bojorge B., Espinosa-Padilla S., Saez-de-Ocariz M., et al. Hyper-IgE syndrome and autoimmunity in Mexican children. Pediatric Nephrology 2006, 21:1200-1205.
161. Kumanovics A., Perkins S.L., Gilbert H., Cessna M.H., Augustine N.H., Hill H.R. Diffuse large B cell lymphoma in hyper-IgE syndrome due to STAT3 mutation. Journal of Clinical Immunology 2010, 30:886-893.
162. Friedline R.H., Brown D.S., Nguyen H., Kornfeld H., Lee J., Zhang Y., et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. The Journal of Experimental Medicine 2009, 206:421-434.
163. Carreno B.M., Bennett F., Chau T.A., Ling V., Luxenberg D., Jussif J., et al. CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. Journal of Immunology 2000, 165:1352-1356.
164. Yi L.A., Hajialiasgar S., Chuang E. Tyrosine-mediated inhibitory signals contribute to CTLA-4 function in vivo. International Immunology 2004, 16:539-547.
165. Cinek T., Sadra A., Imboden J.B. Cutting edge: tyrosine-independent transmission of inhibitory signals by CTLA-4. Journal of Immunology 2000, 164:5-8.
166. Ide A., Kawasaki E., Abiru N., Sun F., Kobayashi M., Fukushima T., et al. Association between IL-18 gene promoter polymorphisms and CTLA-4 gene 49A/G polymorphism in Japanese patients with type 1 diabetes. Journal of Autoimmunity 2004, 22:73-78.
167. Oliveira E.M., Bar-Or A., Waliszewska A.I., Cai G., Anderson D.E., Krieger J.I., et al. CTLA-4 dysregulation in the activation of myelin basic protein reactive T cells may distinguish patients with multiple sclerosis from healthy controls. Journal of Autoimmunity 2003, 20:71-81.
168. Jury E.C., Flores-Borja F., Kalsi H.S., Lazarus M., Isenberg D.A., Mauri C., et al. Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. European Journal of Immunology 2010, 40:569-578.
169. Flores-Borja F., Jury E.C., Mauri C., Ehrenstein M.R. Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:19396-19401.
170. Jacobson E.M., Tomer Y. The CD40, CTLA-4, thyroglobulin, TSH receptor, and PTPN22 gene quintet and its contribution to thyroid autoimmunity: back to the future. Journal of Autoimmunity 2007, 28:85-98.
171. Scheinecker C., Bonelli M., Smolen J.S. Pathogenetic aspects of systemic lupus erythematosus with an emphasis on regulatory T cells. Journal of Autoimmunity 2010, 35:269-275.
172. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003, 299:1033-1036.
173. Xu L., Kitani A., Fuss I., Strober W. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. Journal of Immunology 2007, 178:6725-6729.
174. Valencia X., Stephens G., Goldbach-Mansky R., Wilson M., Shevach E.M., Lipsky P.E. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006, 108:253-261.
175. Dick A.D., Duncan L., Hale G., Waldmann H., Isaacs J. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. Journal of Autoimmunity 1998, 11:255-264.
176. Liu Z., Jiu J., Liu S., Fa X., Li F., Du Y. Blockage of tumor necrosis factor prevents intestinal mucosal inflammation through down-regulation of interleukin-23 secretion. Journal of Autoimmunity 2007, 29:187-194.
177. Hickman-Brecks C.L., Racz J.L., Meyer D.M., LaBranche T.P., Allen P.M. Th17 cells can provide B cell help in autoantibody induced arthritis. Journal of Autoimmunity 2011, 36:65-75.
178. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. The Journal of Clinical Investigation 1999, 103:1345-1352.
179. Gooden M.J., de Bock G.H., Leffers N., Daemen T., Nijman H.W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. British Journal of Cancer 2011, 105:93-103.
180. Marshall N.A., Christie L.E., Munro L.R., Culligan D.J., Johnston P.W., Barker R.N., et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004, 103:1755-1762.
181. Yang Z.Z., Novak A.J., Stenson M.J., Witzig T.E., Ansell S.M. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 2006, 107:3639-3646.
182. Yano H., Ishida T., Inagaki A., Ishii T., Kusumoto S., Komatsu H., et al. Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. International journal of cancer Journal international du cancer 2007, 120:2052-2057.
183. Gjerdrum L.M., Woetmann A., Odum N., Hother C., Henrik-Nielsen R., Gniadecki R., et al. FOXP3 positive regulatory T-cells in cutaneous and systemic CD30 positive T-cell lymphoproliferations. European Journal of Haematology 2008, 80:483-489.
184. Beyer M., Kochanek M., Giese T., Endl E., Weihrauch M.R., Knolle P.A., et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006, 107:3940-3949.
185. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
186. Takahashi H., Numasaki M., Lotze M.T., Sasaki H. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunology Letters 2005, 98:189-193.
187. Prabhala R.H., Pelluru D., Fulciniti M., Prabhala H.K., Nanjappa P., Song W., et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010, 115:5385-5392.
188. Galand C., Donnou S., Crozet L., Brunet S., Touitou V., Ouakrim H., et al. Th17 cells are involved in the local control of tumor progression in primary intraocular lymphoma. PloS One 2011, 6:e24622.
189. Sharfe N., Dadi H.K., Shahar M., Roifman C.M. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proceedings of the National Academy of Sciences of the United States of America 1997, 94:3168-3171.
190. Baecher-Allan C., Hafler D.A. Suppressor T cells in human diseases. The Journal of Experimental Medicine 2004, 200:273-276.
191. Huan J., Culbertson N., Spencer L., Bartholomew R., Burrows G.G., Chou Y.K., et al. Decreased FOXP3 levels in multiple sclerosis patients. Journal of Neuroscience Research 2005, 81:45-52.
192. Takahashi M., Nakamura K., Honda K., Kitamura Y., Mizutani T., Araki Y., et al. An inverse correlation of human peripheral blood regulatory T cell frequency with the disease activity of ulcerative colitis. Digestive Diseases and Sciences 2006, 51:677-686.
193. Moon H.W., Kim B.H., Park C.M., Hur M., Yun Y.M., Kim S.Y., et al. CD4+CD25highFoxP3+ regulatory T-cells in hematologic diseases. The Korean Journal of Laboratory Medicine 2011, 31:231-237.
194. Nadal E., Garin M., Kaeda J., Apperley J., Lechler R., Dazzi F. Increased frequencies of CD4(+)CD25(high) T(regs) correlate with disease relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK 2007, 21:472-479.
195. Kordasti S.Y., Ingram W., Hayden J., Darling D., Barber L., Afzali B., et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110:847-850.
196. Ferraro A., Socci C., Stabilini A., Valle A., Monti P., Piemonti L., et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011, 60:2903-2913.
197. Iwase K., Shimada A., Kawai T., Okubo Y., Kanazawa Y., Irie J., et al. FOXP3/Scurfin gene polymorphism is associated with adult onset type 1 diabetes in Japanese, especially in women and slowly progressive-type patients. Autoimmunity 2009, 42:159-167.
198. Abbasi F., Amiri P., Sayahpour F.A., Pirmoradi S., Abolhalaj M., Larijani B., et al. TGF-beta and IL-23 gene expression in unstimulated PBMCs of patients with diabetes. Endocrine 2012, 41:430-434.
199. Kimura A., Kishimoto T. IL-6: regulator of Treg/Th17 balance. European Journal of Immunology 2010, 40:1830-1835.
200. Alcina A., Fedetz M., Ndagire D., Fernandez O., Leyva L., Guerrero M., et al. IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). PloS One 2009, 4:e4137.
201. Yang J., Chu Y., Yang X., Gao D., Zhu L., Wan L., et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis and Rheumatism 2009, 60:1472-1483.
202. Rana A., Minz R.W., Aggarwal R., Anand S., Pasricha N., Singh S. Gene expression of cytokines (TNF-alpha, IFN-gamma), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 2012.
203. Barreto M., Ferreira R.C., Lourenco L., Moraes-Fontes M.F., Santos E., Alves M., et al. Low frequency of CD4+CD25+ Treg in SLE patients: a heritable trait associated with CTLA4 and TGFbeta gene variants. BMC Immunology 2009, 10:5.
204. Katsifis G.E., Rekka S., Moutsopoulos N.M., Pillemer S., Wahl S.M. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. The American Journal of Pathology 2009, 175:1167-1177.
205. Geri G., Terrier B., Rosenzwajg M., Wechsler B., Touzot M., Seilhean D., et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease. The Journal of Allergy and Clinical Immunology 2011, 128:655-664.
206. Chi W., Zhu X., Yang P., Liu X., Lin X., Zhou H., et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Investigative Ophthalmology and Visual Science 2008, 49:3058-3064.
207. Hamzaoui K., Bouali E., Ghorbel I., Khanfir M., Houman H., Hamzaoui A. Expression of Th-17 and RORgammat mRNA in Behcet's Disease. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research 2011, 17:CR227-CR234.
208. Hamzaoui K., Borhani Haghighi A., Ghorbel I.B., Houman H. RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behcet's disease. Journal of Neuroimmunology 2011, 233:249-253.
209. Hamzaoui K. Th17 cells in Behcet's disease: a new immunoregulatory axis. Clinical and Experimental Rheumatology 2011, 29:S71-S76.
210. Eastaff-Leung N., Mabarrack N., Barbour A., Cummins A., Barry S. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. Journal of Clinical Immunology 2010, 30:80-89.
211. Farago B., Magyari L., Safrany E., Csongei V., Jaromi L., Horvatovich K., et al. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Annals of the Rheumatic Diseases 2008, 67:248-250.
212. Hradsky O., Dusatkova P., Lenicek M., Bronsky J., Nevoral J., Vitek L., et al. The CTLA4 variants may interact with the IL23R- and NOD2-conferred risk in development of Crohn's disease. BMC Medical Genetics 2010, 11:91.
213. Fenoglio D., Bernuzzi F., Battaglia F., Parodi A., Kalli F., Negrini S., et al. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmunity Reviews 2012.
214. Harada K., Shimoda S., Sato Y., Isse K., Ikeda H., Nakanuma Y. Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis. Clinical and Experimental Immunology 2009, 157:261-270.
215. Zhang L., Yang X.Q., Cheng J., Hui R.S., Gao T.W. Increased Th17 cells are accompanied by FoxP3(+) Treg cell accumulation and correlated with psoriasis disease severity. Clinical Immunology 2010, 135:108-117.
216. Cargill M., Schrodi S.J., Chang M., Garcia V.E., Brandon R., Callis K.P., et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. American Journal of Human Genetics 2007, 80:273-290.
217. Gao L., Li K., Li F., Li H., Liu L., Wang L., et al. Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. Journal of Dermatological Science 2010, 57:51-56.
218. Liu Y., Helms C., Liao W., Zaba L.C., Duan S., Gardner J., et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genetics 2008, 4:e1000041.
219. Sugiyama H., Matsue H., Nagasaka A., Nakamura Y., Tsukamoto K., Shibagaki N., et al. CD4+CD25high regulatory T cells are markedly decreased in blood of patients with pemphigus vulgaris. Dermatology 2007, 214:210-220.
220. Arakawa M., Dainichi T., Ishii N., Hamada T., Karashima T., Nakama T., et al. Lesional Th17 cells and regulatory T cells in bullous pemphigoid. Experimental Dermatology 2011, 20:1022-1024.
221. Rensing-Ehl A., Gaus B., Bruckner-Tuderman L., Martin S.F. Frequency, function and CLA expression of CD4+CD25+FOXP3+ regulatory T cells in bullous pemphigoid. Experimental Dermatology 2007, 16:13-21.
222. Oiso N., Suzuki T., Fukai K., Katayama I., Kawada A. Nonsegmental vitiligo and autoimmune mechanism. Dermatology Research and Practice 2011, 2011:518090.
223. Tu C.X., Jin W.W., Lin M., Wang Z.H., Man M.Q. Levels of TGF-beta(1) in serum and culture supernatants of CD4(+)CD25 (+) T cells from patients with non-segmental vitiligo. Archives of Dermatological Research 2011, 303:685-689.
224. Petukhova L., Duvic M., Hordinsky M., Norris D., Price V., Shimomura Y., et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 2010, 466:113-117.
225. Lew B.L., Cho H.R., Haw S., Kim H.J., Chung J.H., Sim W.Y. Association between IL17A/IL17RA gene polymorphisms and susceptibility to alopecia areata in the Korean population. Annals of Dermatology 2012, 24:61-65.
226. Hall A.M., Zamzami O.M., Whibley N., Hampsey D.P., Haggart A.M., Vickers M.A., et al. Production of the effector cytokine interleukin-17, rather than interferon-gamma, is more strongly associated with autoimmune hemolytic anemia. Haematologica 2012.
227. Zhao L., Tang Y., You Z., Wang Q., Liang S., Han X., et al. Interleukin-17 contributes to the pathogenesis of autoimmune hepatitis through inducing hepatic interleukin-6 expression. PloS One 2011, 6:e18909.
228. Yu H., Huang J., Liu Y., Ai G., Yan W., Wang X., et al. IL-17 contributes to autoimmune hepatitis. Journal of Huazhong University of Science and Technology Medical sciences = Hua zhong ke ji da xue xue bao Yi xue Ying De wen ban = Huazhong keji daxue xuebao Yixue Yingdewen ban 2010, 30:443-446.
229. Okumura A., Ishikawa T., Sato S., Yamauchi T., Oshima H., Ohashi T., et al. Deficiency of forkhead box P3 and cytotoxic T-lymphocyte-associated antigen-4 gene expressions and impaired suppressor function of CD4(+)CD25(+) T cells in patients with autoimmune hepatitis. Hepatology Research: The Official Journal of the Japan Society of Hepatology 2008, 38:896-903.
230. Zhang L., Ma J., Takeuchi M., Usui Y., Hattori T., Okunuki Y., et al. Suppression of experimental autoimmune uveoretinitis by inducing differentiation of regulatory T cells via activation of aryl hydrocarbon receptor. Investigative Ophthalmology and Visual Science 2010, 51:2109-2117.
231. Aricha R., Feferman T., Scott H.S., Souroujon M.C., Berrih-Aknin S., Fuchs S. The susceptibility of Aire(-/-) mice to experimental myasthenia gravis involves alterations in regulatory T cells. Journal of Autoimmunity 2011, 36:16-24.
232. Zhang Y., Wang H.B., Chi L.J., Wang W.Z. The role of FoxP3+CD4+CD25hi Tregs in the pathogenesis of myasthenia gravis. Immunology Letters 2009, 122:52-57.
233. Huang S., Li L., Liang S., Wang W. Conversion of peripheral CD4(+)CD25(-) T cells to CD4(+)CD25(+) regulatory T cells by IFN-gamma in patients with Guillain-Barre syndrome. Journal of Neuroimmunology 2009, 217:80-84.
234. Liang S.L., Wang W.Z., Huang S., Wang X.K., Zhang S., Wu Y. Th17 helper cell and T-cell immunoglobulin and mucin domain 3 involvement in Guillain-Barre syndrome. Immunopharmacology and Immunotoxicology 2012.
235. Huber A.K., Jacobson E.M., Jazdzewski K., Concepcion E.S., Tomer Y. Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. The Journal of Clinical Endocrinology and Metabolism 2008, 93:1077-1081.
236. Takahashi M., Kimura A. HLA and CTLA4 polymorphisms may confer a synergistic risk in the susceptibility to Graves' disease. Journal of Human Genetics 2010, 55:323-326.
237. Owen C.J., Eden J.A., Jennings C.E., Wilson V., Cheetham T.D., Pearce S.H. Genetic association studies of the FOXP3 gene in Graves' disease and autoimmune Addison's disease in the United Kingdom population. Journal of Molecular Endocrinology 2006, 37:97-104.
238. Figueroa-Vega N., Alfonso-Perez M., Benedicto I., Sanchez-Madrid F., Gonzalez-Amaro R., Marazuela M. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis. The Journal of Clinical Endocrinology and Metabolism 2010, 95:953-962.
239. Tomer Y. Genetic susceptibility to autoimmune thyroid disease: past, present, and future. Thyroid: Official Journal of the American Thyroid Association 2010, 20:715-725.
240. Ooi J.D., Phoon R.K., Holdsworth S.R., Kitching A.R. IL-23, not IL-12, directs autoimmunity to the Goodpasture antigen. Journal of the American Society of Nephrology: JASN 2009, 20:980-989.
241. Alenzi F.Q., Salem M.L., Alenazi F.A., Wyse R.K. Cellular and molecular aspects of Goodpasture syndrome. Iranian Journal of Kidney Diseases 2012, 6:1-8.
242. Ustun C., Miller J.S., Munn D.H., Weisdorf D.J., Blazar B.R. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?. Blood 2011, 118:5084-5095.
243. Hus I., Tabarkiewicz J., Lewandowska M., Wasiak M., Wdowiak P., Kusz M., et al. Evaluation of monocyte-derived dendritic cells, T regulatory and Th17 cells in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Folia histochemica et cytobiologica/Polish Academy of Sciences. Polish Histochemical and Cytochemical Society 2011, 49:153-160.
244. Beyer M., Kochanek M., Darabi K., Popov A., Jensen M., Endl E., et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106:2018-2025.
245. Jain P., Javdan M., Feger F.K., Chiu P.Y., Sison C., Damle R.N., et al. Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica 2012, 97:599-607.
246. Yang Z.Z., Novak A.J., Ziesmer S.C., Witzig T.E., Ansell S.M. Malignant B cells skew the balance of regulatory T cells and TH17 cells in B-cell non-Hodgkin's lymphoma. Cancer Research 2009, 69:5522-5530.
247. Feyler S., Scott G.B., Parrish C., Jarmin S., Evans P., Short M., et al. Tumour cell generation of inducible regulatory T-cells in multiple myeloma is contact-dependent and antigen-presenting cell-independent. PloS One 2012, 7:e35981.
248. Karabon L., Pawlak-Adamska E., Tomkiewicz A., Jedynak A., Kielbinski M., Woszczyk D., et al. Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population. Pathology Oncology Research: POR 2012, 18:219-226.
249. Shen H., Goodall J.C., Hill Gaston J.S. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis and Rheumatism 2009, 60:1647-1656.
250. Kurasawa K., Hirose K., Sano H., Endo H., Shinkai H., Nawata Y., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis and Rheumatism 2000, 43:2455-2463.
251. Beyer M., Schultze J.L. Regulatory T cells in cancer. Blood 2006, 108:804-811.